Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations

MT Newswires Live
01-01

The Dow Jones Industrial Average and the S&P 500 were basically flat, while the Nasdaq Composite was down in late-morning trading on the final day of the year.

Sangamo Therapeutics (SGMO) said late Monday it will regain full development and commercialization rights for its prospective hemophilia A gene therapy after Pfizer (PFE) opted to terminate its collaboration and licensing agreement with the company. The partnership between Sangamo and Pfizer will formally end in April 21, 2025, Sangamo said. Shares of Sangamo were down 53.8%, while those of Pfizer were up 0.2%.

Dave (DAVE) denied allegations by the Justice Department that it misled customers with advertisements of cash advances, calling the complaint a case of "government overreach." The Justice Department said Monday it filed a complaint against Dave and Chief Executive Jason Wilk alleging that the company lured customers to its personal finance app by promising cash advances of up to $500 that many did not receive. Dave shares were down 7.7%.

The Federal Housing Finance Agency's measure of home prices rose by 0.4% in October, matching expectations of a survey compiled by Bloomberg as of 7:35 a.m. ET. Prices were up 4.5% from a year earlier in October.

Price: 1.08, Change: -1.26, Percent Change: -53.76

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10